Molecular biology of prostate cancer

World Journal of Urology

Volumn 14, Issue 5, 1996, Pages 318-328

  Shi, X B ^a   Gumerlock, P H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DNA; TUMOR MARKER;

ANIMAL; DNA METHYLATION; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; MOLECULAR BIOLOGY; ONCOGENE; PROSTATE TUMOR; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA METHYLATION; DNA, NEOPLASM; GENES, BCL-2; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MOLECULAR BIOLOGY; NEOPLASM METASTASIS; ONCOGENES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0030346702     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00184605     Document Type: Article

References (139)

1. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC (1995) The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 75:522-529
2. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M (1992) Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52:5991-5996
3. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C (1994) Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151:1276-1280
4. Bergerheim US, Kunimi K, Collins VP, Ekman P (1991) Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer 3:215-220
5. Berner A, Geitvik G, Karlsen F, Fossa SD, Nesland JM, Borresen AL (1995) TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumor tissue. J Pathol 176:299-308
6. Blount LV, Cooke DB III (1996) Genomic methylation patterns of the Dunning R-3327 prostate adenocarcinoma system. Cancer Lett 98:213-218
7. Bookstein R (1994) Tumor suppressor genes in prostate oncogenesis. J Cell Biochem [Suppl] 19:217-223
8. Bookstein R, Allred D (1993) Recessive oncogene. Cancer 71 : 1179-1186
9. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene. Science 247:712-715
10. Bookstein R, Rio P, Madreperla S, Hong F, Allred C, Crizzle WE, Lee WH (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sei USA 87:7762-7766
11. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC (1993) P53 is mutated in a subset of advancedstage prostate cancers. Cancer Res 53:3369-3373
12. Borchers H, Meyers FJ, Gumerlock PH, Stewart SL, deVere White RW (1996) NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas. J Urol 155: 2080-2084
13. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869-3873
14. Brooks JD, Bova GS, Isaacs WB (1995) Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinoma. Prostate 26:35-39
15. Burney TL, Rockove S, Eiseman JL, Jacobs SC, Kyprianou N ( 1994) Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate 25:177-188
16. Bussemakers MJ, Giroldi LA, Bokhoven A van, Schalken JA (1994) Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines characterization of the human E-cadherin gene promoter. Biochem Biophys Res Commun 203:1284-1290
17. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA (1987) Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11:327-337
18. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A. Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D (1995) Frequency of homozygous deletion at p!6/CDKN2 in primary human tumors. Nat Genet 11:210-212
19. Carruba G, Leake RE, Rinaldi F, Chalmers D, Comito L. Sorci C, Pavone-Macaluso M, Castagnetta LA (1994) Steroidgrowth factor interaction in human prostate cancer. 1. Shortterm effects of transforming growth factors on growth of human prostate cancer cells. Steroids 59:412-420
20. Carter BS, Epstein JI, Isaacs WB (1990) RAS gene mutations in human prostate cancer. Cancer Res 50:6830-6832
21. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB (1990) Allelic loss of chromosome 16q and lOq in human prostate cancer. Proc Natl Acad Sei USA 87:8751-8755
22. Castagnaro M, Yandell DW, Dockhorn-Dworhiczak B, Wolfe HJ, Poremba C (1993) Human androgen receptor gene mutation and p53 gene analysis in advanced prostate cancer. Verh Dtsch Ges Pathol 77:119-123
23. Chen M, Quintans J, Fuks Z, Thompson C, Kufe DW, Weichselbaum RR (1995) Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor a, and ceramide. Cancer Res 55:991-994
24. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG (1996) Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 148:1375-1380
25. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH (1994) P53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 86:926-933
26. Cho KR, Vogelstein B (1992) Genetic alterations in the adenoma-carcinoma sequence. Cancer 70: 1727-1731
27. Chodak GW, Krane DM, Puy LA. Takeda H, Johnson K. Chang C (1992) Nuclear localization of androgen receptor in heterogeneous samples of the normal, hyperplastic and neoplastic human prostate. J Urol 147:798-803
28. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo C (1994) Expression of transforming growth factor-a and the epidermal growth factor receptor in human prostate tissues. J Urol 152:2120-2124
29. Colombel M, Symmans F, Gil S, OToole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S. Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormonerefractory human prostate cancers. Am J Pathol 143:390-400
30. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A. Radmayr C. Eberle J, Bartsch G, Klocker H (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541-1550
31. deVere White RW, Gumerlock PH, Chamberlain SR. Lee F, Siders DB (1994) Human androgen receptor analysis in prostate cancer (abstract). J Urol 151 :468 A
32. Dinjens WN, Weiden MM van der, Schroeder FH, Bosnian FT, Trapman J (1994) Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56:630-633
33. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC (1995) KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11 p 11.2. Science 268:884-886
34. Eagle LR, Yin XY, Brothman AR, Williams BJ, Atkin NB, Prochownik EV (1995) Mutation of the MXI1 gene in prostate cancer. Nat Genet 9:249-255
35. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC (1995) Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1 : 1111-1118
36. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC (1995) Transforming growth factorβl: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73:628-635
37. Effert PJ, Strohmeyer TG (1994) Basic research in prostate cancer: molecular biology. Acta Urol Belg 62:15-21
38. Effert PJ, McCoy RH, Walther PJ, Liu ET (1993) P53 gene alterations in human prostate carcinoma. J Urol 150:257-261
39. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y (1994) WAF1/CIP1 is induced in p53-mediated Gl arrest and apoptosis. Cancer Res 54:1169-1174
40. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang ZP, Bostwick DG, Liotta LA, Linehan WM (1995) Allelic loss on chromosome 8p 12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55:2959-2962
41. L Fearon ER, Vogelstein B (1990) A genetic model forcolorectal tumorigenesis. Cell 61:759-767
42. Fishman JR, Gumerlock PH, Meyers FJ, deVere White RW (1994) Quantitation of NM23 expression in human prostate tissues. J Urol 152:202-207
43. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT (1996) Expression of Bcl2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 2:389-398
44. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864
45. Gao X, Zacharek A, Grignon DJ, Sakr W, Powell IJ, Porter AT, Honn KV (1995) Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer. Oncogene 11:1241-1247
46. Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT, Honn KV (1995) Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11: 1395-1398
47. Graft'JR. Herman JG, Lapidus RG, Chopra H. Xu R, Jarrard DF. Isaacs WB, Pitha PM, Davidson NE. Bay lin SB (1995) E-cadherin expression is silenced by DNA hypermethylalion in human breast and prostate carcinomas. Cancer Res 55 : 5195-5199
48. Gudmundsson J. Johannesdottir G. Bergthorsson JT. Arason A, Ingvarsson S, Egilsson V, Barkardottir RB (1995) Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13ql2-ql3. Cancer Res 55:4830-4832
49. Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW (1991 ) Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 51 : 1632-1637
50. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW (1996) P53 abnormalities in primary prostate cancer: SSCP analysis of cDNA detects rare mutant transcripts. J Natl Cancer Inst (submitted, in press)
51. Hall MC, Zagars OK, Novone NM, Eschenbach AC von, Troncoso P, Conti CJ, Pollack A, Chung LW (1995) Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45:470-475
52. Harriss DR. Savill J (1995) Apoptosis and the prostate. Br J Urol75 [Suppl 11:27-33
53. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard OS, Moul JW, Srivastava S (1995) Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancers. J Urol 154:414-421
54. Hennessy C, Henry JA, May FE, Westley BR, Angus B, Lennard TW (1991) Expression of the antimetastatic gene NM23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst 83:281-285
55. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the CDKN2/pl6/MTSl gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530
56. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sei US A 88:6961-6965
57. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) P53 mutation in human cancers. Science 253:49-53
58. Ichikawa T, Ichikawa Y, Dong JT, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barren JC, Isaacs JT (1992) Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 52 : 3486-3490
59. Igawa M, Rukstalis DB, Tanabe T, Chodak GW (1994) High levels of NM23 expression are related to cell proliferation in human prostate cancer. Cancer Res 54: 1313-1318
60. Isaacs WB, Carter BS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720
61. Isaacs WB, Bova OS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM (1994) Molecular biology of prostate cancer. SeminOncol21:514-52l
62. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM (1994) Genetic alteration in prostate cancer. Cold Spring Harb Symp Quant Biol LIX : 653-659
63. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM (1995) Molecular biology of prostate cancer progression. Cancer Surv 23:19-32
64. Ittmann MM, Wieczorek R (1996) Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol 27:28-34
65. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Classman AB, Eschenbach AC von, Troncoso P (1995) Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11:2121-2126
66. Kallakury BV, Figge J, Leibovich B, Hwang J, Rifkin M. Kaufman R, Figge HL, Nazeer T, Ross JS (1996) Increased
67. bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation. Mod Pathol 9:41-47
68. Kirn 1Y, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kalo M, Lee C (1996) Genetic change in transforming growth factor β(TGF-β) receptor type I gene correlates with insensitivity to TGF-β l in human prostate cancer cells. Cancer Res 56:44-48
69. Knabbe C, Klein H, Zugmaier G, Voigt KD ( 1993) Hormonal regulation of transforming growth factor β-2 expression in human prostate cancer. J Steroid Biochem Mol Biol 47: 137-142
70. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J (1995) Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86:622-625
71. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM ( 1992) K-ras activation and ras p21 expression in latent prostatic carcinomas in Japanese men. Cancer 69:22932299
72. Konishi N, Hiasa Y. Hayashi I, Matsuda H, Tsuzuki T, Ming T, Kitahori Y, Shiraishi T, Yatani R, Shimazaki J (1995) P53 mutations occur in clinical, but not latent, human prostate carcinoma. Jpn J Cancer Res 86:57-63
73. Kopp A, Jonat W, Schmahl M, Knabbe C (1995) Transforming growth factor β2 (TGF-β2) levels in plasma of patients with metastatic breast cancer treated with Tamoxifen. Cancer Res 55:4512-4515
74. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, Danenberg PV (1995) Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27:18-24
75. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T (1995) Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27:314320
76. Kühn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW (1993) Expression of the c-erb B-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 150: 1427-1433
77. Latil A, Baron JC, Cussenot O, Fournier G, Soussi T, Boccon-Gibod L, Due AL, Rouesse J, Lidereau R (1994) Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer 11 : 119-125
78. Lee WH. Morion RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WS, Nelson WG (1994) Cytidine methylation of regulatory sequences near the 7i-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sei USA 91:11 733-11 737
79. Levine AJ, Momand J, Finaly CA (1991) The p53 tumor suppressor gene. Nature 351 :453-456
80. Liu XH, Wiley HS. Meikle AW (1993) Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-a (TGF-cc) and epidermal growth factor (EGF)/TGF-a receptor. J Clin Endocrinol Metab 77: 1472-1478
81. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D. Bookstein R (1994) Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer 10: 151-159
82. Makos M, Nelkin BD, Lerman MI, Latif F, Zbar B, Baylin SB (1992) Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sei USA 89: 1929-1933
83. Massenkeil G, Oberhuber H, Hailemariam S, SulserT, Diener PA, Bannwart F, Schafer R, Schwarte-Waldhoff I (1994) P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p. and 18q are confined to advanced prostate cancer. Anticancer Res 14:2785-2790
84. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT. Tu SM, Campbell ML (1992) Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
85. McLellan DL, Norman RW (1995) Hereditary aspects of prostate cancer. Can Med Assoc J 153 :895-900
86. Mirchandani D, Zheng JP, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P (1995) Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. AmJPathol 147:92-101
87. Morton RA, Bova GS, Isaacs WB (1993) Hypermethylation of chromosome 17pl3.3 in human adenocarcinoma of the prostate (abstract). J Urol 149:376A
88. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH (1992) Infrequent RAS oncogene mutations in human prostate cancer. Prostate 20:327-338
89. Muir GH, Butta A, Shearer RJ, Fisher C, Dearnaley DP, Flanders KC, Sporn MB, Colletta AA (1994) Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer 69:130-134
90. Mydlo JH, Macchia RJ (1992) Growth factors in urologie tissues: detection, characterization, and clinical applications. Urology 40:491-498
91. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, Eschenbach AC von, Conti CJ (1993) P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669
92. Netto GJ, Humphrey PA (1994) Molecular biologic aspects of human prostatic carcinoma. Am J Clin Pathol 102 [Suppl 1J : S 57-S 64
93. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER (1992) Androgen receptor gene mutation in human prostate cancer. Proc Natl Acad Sei USA 89:6319-6323
94. Parker SL, Tong T, Bolden S, Wingo (1996) Cancer statistics, 1996. CA 46:5-27
95. Peehl DM (1993) Oncogenes in prostate cancer: an update. Cancer 71:1159-1164
96. Peehl DM, Wehner N, Stamey TA (1987) Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 10: 281-289
97. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemos JP (1994) Loss of the retinoblastoma susceptibility gene (Rbl) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70:1252-1257
98. Pisters LL, Troncoso P, Zhau HE, Li W, Eschenbach AC von, Chung LW (1995) C-MET proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154: 293-298
99. Prendergast NJ, Walther PJ (1995) Genetic alterations in prostate adenocarcinoma. Surg Oncol Clin North Am 4:241255
100. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6
101. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT (1994) Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 25:249-265
102. Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, Fisher HA ( 1993) Contribution of Her-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 72:3020-3028
103. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM. VerleunMooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schröder FH, K wast TH van der (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746
104. Rushmore TH, Pickett CB (1993) Glutathione S-transferases: structure, regulation, and therapeutic implications. J Biol Chem 268:11475-1 1478
105. Sadasivan R, Morgan R, Jennings S, Austenfeld M. Veldhuizen P van, Stephens R, Noble M (1993) Overexpression of
106. Her-2/NEU may be an indicator of poor prognosis in prostatecancer. J Urol 150:126-131
107. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, Crissman JD (1994) Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 54:3273-3277
108. Sandberg AA (1992) Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 23:368-380
109. Sarkar FH, Sakr W, Li YW, Macoska J, Ball DE, Crissman JD (1992) Analysis of retinoblastoma (Rb) gene deletion in human prostatic carcinomas. Prostate 21 :145-152
110. Shabaik AS, Krajewski S, Burgan A, Krajewska ML Reed JC (1995) Bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol 3:17-27
111. Sharief Y, Wilson E, Gumerlock PH, deVere White RW, Schalken J, French F, Mohler J (1994) Is hormone refractory prostatic carcinoma associated with androgen receptor mutation or mRNA splicing errors (abstract)? J Urol 151:369A
112. Shen RQ, Su ZZ, Olsson CA, Fisher PB (1995) Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc Natl Acad Sei USA 92:6778-6782
113. Shurbaji MS, Kalbfleisch JH, Thurmond TS (1995) Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 26: 106-109
114. Sobel ME (1990) Metastasis suppressor genes. J Natl Cancer Inst 82:267-276
115. Steiner MS, Barrack ER (1992) Transforming growth factorβl overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 6:15-25
116. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765
117. Szepetowski P, Perucca-Lostanlen D, Gaudray P (1991) Amplification, proto-oncogenes et cancers humains. Med Sei 7: 14
118. Takahashi H, Furusato M, Allsbrook WC Jr, Nishii H, Wakui S, Barrett JC, Boyd J (1995) Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 55:1621-1624
119. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins RB (1995) Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55:4114-4119
120. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J (1996) Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77:934-940
121. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
122. Thompson SJ, Mellon K, Charlton RG, Marsh C, Robinson M, Neal DE (1992) P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol 69: 609-613
123. Thompson TC (1990) Growth factors and oncogenes in prostate cancer. Cancer Cells 2:345-354
124. Tilley WD. Buchanan G, Mickey TE. Bentel JM (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285
125. Tricoli JV, Gumerlock PH. Yao JL, Chi SO, D'Souza SA. Nestok BR, deVere White RW (1996) Alterations of the retinohlastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer 15: 108-1 14
126. Truong LD. Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC (1993) Association of transforming growth factor-βl with prostate cancer: an immunohistochemical study. Hum Pathol 24:4-9
127. Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sei USA 83 : 5214-5218
128. Uchida T, Wada C, Shitara T, Egawa S, Koshiba K (1993) Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer. Br J Cancer 68:751-755
129. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HE, Schaafsma HE, Debruyne FM, Isaacs WB (1992) Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52 : 5104-5109
130. Veldhuizen PJ van, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL (1993) Mutant p53 expression in prostate carcinoma. Prostate 22:23-30
131. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets CA, Claassen E, Rooij HC van, Trapman J, Brinkmann AO, Mulder EA (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540
132. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887
133. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP (1994) P53 oncogene mutations in human prostate cancer specimens. JUrol 151:492-495
134. Vogelstein B, Kanzler K (1993) The multistep nature of cancer. Trends Genet 9:138-141
135. Ware JL (1993) Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev 12:287-301
136. Wilding G (1995) Endocrine control of prostate cancer. Cancer Surv 23:43-62
137. Yaremko ML, Recant WM, Westbrook CA (1995) Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. Genes Chromosomes Cancer 13 : 186-191
138. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ (1994) Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1 Cancer Res 54:6370-6373
139. Zhau HZ, Wan DS, Zhou JX, Miller GJ, Eschenbach AC von (1992) Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissue and cell lines. Mol Carcinog 5:320327